Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer

DOI: https://doi.org/10.1186/s13046-022-02464-5

2022-09-24

Abstract:Adrenocortical cancer (ACC) is a rare and aggressive cancer with dismal 5-year survival due to a lack of effective treatments. We aimed to identify a new effective combination of drugs and investigated their synergistic efficacy in ACC preclinical models.

oncology

What problem does this paper attempt to address?

Molecular Cluster Mining of Adrenocortical Carcinoma Via Multi-Omics Data Analysis Aids Precise Clinical Therapy.

Yu Guan,Shaoyu Yue,Yiding Chen,Yuetian Pan,Lingxuan An,Hexi Du,Chaozhao Liang

DOI: https://doi.org/10.3390/cells11233784

IF: 6

2022-01-01

Cells

Abstract:Adrenocortical carcinoma (ACC) is a malignancy of the endocrine system. We collected clinical and pathological features, genomic mutations, DNA methylation profiles, and mRNA, lncRNA, microRNA, and somatic mutations in ACC patients from the TCGA, GSE19750, GSE33371, and GSE49278 cohorts. Based on the MOVICS algorithm, the patients were divided into ACC1-3 subtypes by comprehensive multi-omics data analysis. We found that immune-related pathways were more activated, and drug metabolism pathways were enriched in ACC1 subtype patients. Furthermore, ACC1 patients were sensitive to PD-1 immunotherapy and had the lowest sensitivity to chemotherapeutic drugs. Patients with the ACC2 subtype had the worst survival prognosis and the highest tumor-mutation rate. Meanwhile, cell-cycle-related pathways, amino-acid-synthesis pathways, and immunosuppressive cells were enriched in ACC2 patients. Steroid and cholesterol biosynthetic pathways were enriched in patients with the ACC3 subtype. DNA-repair-related pathways were enriched in subtypes ACC2 and ACC3. The sensitivity of the ACC2 subtype to cisplatin, doxorubicin, gemcitabine, and etoposide was better than that of the other two subtypes. For 5-fluorouracil, there was no significant difference in sensitivity to paclitaxel between the three groups. A comprehensive analysis of multi-omics data will provide new clues for the prognosis and treatment of patients with ACC.
Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics

Jie Zhang,Luming Wu,Tingwei Su,Haoyu Liu,Lei Jiang,Yiran Jiang,Zhiyuan Wu,Lu Chen,Haorong Li,Jie Zheng,Yingkai Sun,Hangya Peng,Rulai Han,Guang Ning,Lei Ye,Weiqing Wang

DOI: https://doi.org/10.3389/fendo.2024.1365321

IF: 6.055

2024-05-08

Frontiers in Endocrinology

Abstract:Background: Adrenocortical carcinoma (ACC) is an aggressive endocrine malignancy with limited therapeutic options. Treating advanced ACC with mitotane, the cornerstone therapy, remains challenging, thus underscoring the significance to predict mitotane response prior to treatment and seek other effective therapeutic strategies. Objective: We aimed to determine the efficacy of mitotane via an in vitro assay using patient-derived ACC cells (PDCs), identify molecular biomarkers associated with mitotane response and preliminarily explore potential agents for ACC. Methods: In vitro mitotane sensitivity testing was performed in 17 PDCs and high-throughput screening against 40 compounds was conducted in 8 PDCs. Genetic features were evaluated in 9 samples using exomic and transcriptomic sequencing. Results: PDCs exhibited variable sensitivity to mitotane treatment. The median cell viability inhibition rate was 48.4% (IQR: 39.3-59.3%) and -1.2% (IQR: -26.4-22.1%) in responders (n=8) and non-responders (n=9), respectively. Median IC50 and AUC were remarkably lower in responders (IC50: 53.4 μM vs 74.7 μM, P<0.0001; AUC: 158.0 vs 213.5, P<0.0001). Genomic analysis revealed CTNNB1 somatic alterations were only found in responders (3/5) while ZNRF3 alterations only in non-responders (3/4). Transcriptomic profiling found pathways associated with lipid metabolism were upregulated in responder tumors whilst CYP27A1 and ABCA1 expression were positively correlated to in vitro mitotane sensitivity. Furthermore, pharmacologic analysis identified that compounds including disulfiram, niclosamide and bortezomib exhibited efficacy against PDCs. Conclusion: ACC PDCs could be useful for testing drug response, drug repurposing and guiding personalized therapies. Our results suggested response to mitotane might be associated with the dependency on lipid metabolism. CYP27A1 and ABCA1 expression could be predictive markers for mitotane response, and disulfiram, niclosamide and bortezomib could be potential therapeutics, both warranting further investigation.

endocrinology & metabolism
The effectiveness of targeted therapy for recurrence or metastasis adenoid cystic carcinoma: a systematic review and meta-analysis

Lu Zhang,Hao-Nan Yang,Ying Wang,Dan Li,Zheng Lei,Meng-Qi Yang,Yun-Chang Liu,Jiang He,Yong-Zhong Wu,Jiang-Dong Sui

DOI: https://doi.org/10.1080/07853890.2024.2399867

Abstract:Background and purpose: Several clinical studies have demonstrated the potential of molecular-targeted agents for the treatment of recurrent or metastatic adenoid cystic carcinoma (R/M ACC). However, there is currently no consensus regarding the efficacy of molecular-targeted agents for patients with R/M ACC. This study aimed to evaluate the therapeutic efficacy and safety of molecular-targeted agents in patients with R/M ACC and provide insights to guide clinical decision-making. Materials and methods: Five databases (PubMed, Embase, Cochrane, ProQuest, and Scopus) were searched based on the search strategy and selection criteria. Primary endpoints were objective response rate (ORR) and progression-free survival (PFS). The secondary endpoints were disease control rate (DCR), overall survival (OS), metastatic sites, and adverse events (AE). Pooled estimates were calculated using a random-effects meta-analysis. Results: Finally, 28 studies, involving 849 patients, were included. The most common metastatic sites were the lungs, bones, liver, lymph nodes, and kidneys. The pooled ORR was 4.0% (95% CI, 0.7-8.8%), the pooled DCR was 80.5% (95% CI, 72.2%-87.7%). Compared with other-target drugs, multiple kinase inhibitors (MKIs) improved the ORR (pooled ORR for single-target drugs vs. MKIs: 5.9% vs. 0%). The combination of MKIs and immune checkpoint inhibitors (ICIs) had a significantly higher ORR (17.9% in the axitinib + avelumab group). The pooled median PFS and OS were 8.35 and 25.62 months, respectively. MKIs improved the median PFS compared to other-target drugs (9.43 months vs 5.06 months). In addition, the most common adverse events (AEs) were fatigue (51.6%), hypertension (44.2%), and nausea (40.0%), followed by hand-foot skin syndrome (36.8%), diarrhoea (34.4%), weight loss (34.2%), anorexia (31.8%), rash (31.7%), and headache (29.0%). Conclusion: The findings of this study suggest that MKIs have a better therapeutic efficacy than single-target drugs in patients with R/M ACC. Future studies are warranted to verify the synergistic role of the combination strategy of MKIs plus ICIs, given the limited number of studies on this topic conducted and published to date.
Comprehensive genomic analysis of adrenocortical carcinoma reveals genetic profiles associated with patient survival

A Sun-Zhang,C C Juhlin,T Carling,U Scholl,M Schott,C Larsson,S Bajalica-Lagercrantz

DOI: https://doi.org/10.1016/j.esmoop.2024.103617

IF: 6.883

ESMO Open

Abstract:Background: Adrenocortical carcinoma (ACC) is one of the most lethal endocrine malignancies and there is a lack of clinically useful markers for prognosis and patient stratification. Therefore our aim was to identify clinical and genetic markers that predict outcome in patients with ACC. Methods: Clinical and genetic data from a total of 162 patients with ACC were analyzed by combining an independent cohort consisting of tumors from Yale School of Medicine, Karolinska Institutet, and Düsseldorf University (YKD) with two public databases [The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO)]. We used a novel bioinformatical pipeline combining differential expression and messenger RNA (mRNA)- and DNA-dependent survival. Data included reanalysis of previously conducted whole-exome sequencing (WES) for the YKD cohort, WES and RNA data for the TCGA cohort, and RNA data for the GEO cohort. Results: We identified 3903 significant differentially expressed genes when comparing ACC and adrenocortical adenoma, and the mRNA expression levels of 461/3903 genes significantly impacted survival. Subsequent analysis revealed 45 of these genes to be mutated in patients with significantly worse survival. The relationship was significant even after adjusting for stage and age. Protein-protein interaction showed previously unexplored interactions among many of the 45 proteins, including the cancer-related proteins DNA polymerase delta 1 (POLD1), aurora kinase A (AURKA), and kinesin family member 23 (KIF23). Furthermore 14 of the proteins had significant interactions with TP53 which is the most frequently mutated gene in the germline of patients with ACC. Conclusions: Using a multiparameter approach, we identified 45 genes that significantly influenced survival. Notably, many of these genes have protein interactions not previously implicated in ACC. These findings may lay the foundation for improved prognostication and future targeted therapies.
A meta-analysis of overall survival and response in metastatic adrenocortical carcinoma: A review of 23 prospective trials of 880 patients.

Angus Hall,Megan Crumbaker,James Pham,Jia (Jenny) Liu,Hao-Wen Sim,Anthony M. Joshua

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.4

IF: 45.3

2024-02-01

Journal of Clinical Oncology

Abstract:4 Background: Metastatic adrenocortical carcinoma (mACC) is a rare, aggressive tumour of the adrenal gland, with historically poor survival and limited established treatment modalities. The aim of this study was to systematically search for and analyse all prospective trials for mACC to establish benchmark response and survival outcomes. The study was registered on PROSPERO CRD42023430557. Methods: A systematic review and meta-analysis of five databases was performed between June 2023- July 2023. Key outcomes extracted included patient demographics, overall survival (OS), progression-free survival (PFS) and objective response rates (ORR). ORR was calculated using a random effects model and inverse variance methods. Time-to-event outcomes including PFS and OS, were extracted digitally from available Kaplan- Meier curves using the IPDfromKM tool and individual patient data (IPD) was generated as per Guyot et al. The PFS and OS data from individual studies were then pooled using a multivariate extension of the DerSimonian–Laird method to generate summary survival curves. Results: The final 23 trials (5 Phase 1b, 16 Phase II and 3 Phase 3) encompassed 880 patients were retrieved. Pooled ORR was 9.0% overall (2.9% for targeted therapy, 12.3% for chemotherapy and 15.3% for immunotherapy). Median OS was 9.9 months (7.4 months for targeted therapy, 11.2 months for chemotherapy and 10.6 months for immunotherapy). Median PFS was 2.6 months (2.7 months for targeted therapy, 3.0 months for chemotherapy and 2.1 months for immunotherapy). Kaplan-Meier curves for OS were available for 10 treatment lines (n = 605), with a pooled median OS of 9.9 months (95% CI 7.7-11.9) and 12-month OS of 41.6% (95CI 33.1-51.2). Median OS was 7.4 months for patients receiving targeted therapy (95% CI 4.7–12.0), 11.2 months for patients receiving chemotherapy (95% CI 6.9–14.7) and 10.6 months for patients receiving immunotherapy (95% CI 4.4–13.2]. 12-month OS was 30.4% (95% CI 15.9-58.3) for patients receiving targeted therapy, 45.4% (95% CI 33.7-61.2) for patients receiving chemotherapy and 45.3% (95% CI 36.2-56.6) for patients receiving immunotherapy. Conclusions: This study found that current treatments strategies confer limited survival and response benefit in mACC and highlight the need for research into the pathogenesis and novel strategies in the disease. Immunotherapy and chemotherapy demonstrate modest benefits for patients and future trials should attempt to surpass the survival benchmarks set in this study.

oncology
Combined inhibition of JAK1/2 and DNMT1 by newly identified small-molecule compounds synergistically suppresses the survival and proliferation of cervical cancer cells

Shiqi She,Yang Zhao,Bo Kang,Cheng Chen,Xinyu Chen,Xiaobing Zhang,Wenjie Chen,Songsong Dan,Hangxiang Wang,Ying-Jie Wang,Jinhao Zhao

DOI: https://doi.org/10.1038/s41419-020-02934-8

2020-01-01

Abstract:Despite substantial advances in treating cervical cancer (CC) with surgery, radiation and chemotherapy, patients with advanced CC still have poor prognosis and significantly variable clinical outcomes due to tumor recurrence and metastasis. Therefore, to develop more efficacious and specific treatments for CC remains an unmet clinical need. In this study, by virtual screening the SPECS database, we identified multiple novel JAK inhibitor candidates and validated their antitumor drug efficacies that were particularly high against CC cell lines. AH057, the best JAK inhibitor identified, effectively blocked the JAK/STAT pathways by directly inhibiting JAK1/2 kinase activities, and led to compromised cell proliferation and invasion, increased apoptosis, arrested cell cycles, and impaired tumor progression in vitro and in vivo. Next, by screening the Selleck chemical library, we identified SGI-1027, a DNMT1 inhibitor, as the compound that displayed the highest synergy with AH057. By acting on a same set of downstream effector molecules that are dually controlled by JAK1/2 and DNMT1, the combination of AH057 with SGI-1027 potently and synergistically impaired CC cell propagation via dramatically increasing apoptotic cell death and cell-cycle arrest. These findings establish a preclinical proof of concept for combating CC by dual targeting of JAK1/2 and DNMT1, and provide support for launching a clinical trial to evaluate the efficacy and safety of this drug combination in patients with CC and other malignant tumors.
Identification of a Novel Oral Small-Molecule JAK1/2 Inhibitor and Its Potent Synergistic Drug Combinations Against Cervical Cancer

Shiqi She,Yang Zhao,Bo Kang,Cheng Chen,Xinyu Chen,Xiaobing Zhang,Wenjie Chen,Songsong Dan,Hangxiang Wang,Ying-Jie Wang,Jinhao Zhao

DOI: https://doi.org/10.2139/ssrn.3502345

2019-01-01

Abstract:Background: Although JAK (Janus Kinase) inhibitors have been widely applied to many types of aggressive tumors with continuously activated JAK/STAT signaling pathways, efficacious compounds against cervical cancer (CC) are still lacking, and chronic exposure to them inevitably results in drug resistance that often arises from compensatory activation of alternative signaling and survival pathways. Therefore, developing novel JAK inhibitors and identifying their partner compounds for combination therapy against CC, remains an unmet clinical need.Methods: In this study, by virtual screening the SPECS database, we selected out multiple JAK inhibitor candidates, validated their kinase activities and antitumor drug efficacies in various biochemical, cellular and in vivo xenograft models. Next, we screened a chemical library containing 2094 small molecules to identify compounds that act synergistically with the best JAK inhibitor obtained above in dampening CC cell propagation. Finally, the molecular mechanism of such synergistic effect was explored.Findings: Twenty potential small-molecule JAK inhibitors were identified by virtual screening, and the top 9 ranking compounds were validated by biochemical assays. AH057, the best JAK inhibitor identified, can effectively block JAK/STAT pathways by directly inhibiting JAK1/2 activities, and exhibits potent antitumor effects including compromised cell proliferation and invasion, increased apoptosis, arrested cell cycles and impaired tumor progression in a xenograft model. Among all cell lines examined, CC cell lines were the most sensitive to AH057. Further, based on the calculated Bliss synergy scores, SGI-1027, a DNMT1 inhibitor, was identified as the best compound that works in high synergy with AH057. The combination of AH057 and SGI-1027 potently induced cell cycle arrest at G1 phase partially through Cyclin D1 and Cyclin A2, and apoptotic cell death that is linked to PARP, Caspase-3, Bcl-xL and Survivin.Interpretation: A novel oral small-molecule JAK1/2 inhibitor AH057 with definitive antitumor efficacy against CC is identified in this study. The combination of AH057 with the DNMT1 inhibitor SGI-1027 synergistically impairs cancer cell propagation via induced apoptosis and cell cycle arrest, likely by acting on a same group of downstream effector molecules that are dually controlled by JAK1/2 and DNMT1. This study provides preclinical support for launching a clinical trial to evaluate the safety and efficacy of this drug combination in patients with CC and other malignant tumors.Funding Statement: This work was supported by grants from the National Key Research and Development Program of China (2016YFA0101201, 2016YFA0100303, 2017YFD0200505), and the National Natural Science Foundation of China (31601103, 31872022).Declaration of Interests: YJW, BK and JZ have a pending patent application titled “Identification of a novel JAK1/2 inhibitor and its synergistic drug combinations against human cancers”. The other authors declared no conflicts of interest.Ethical Approval Statement: The Experimental Animal Ethics Committee of Zhejiang University has approved the animal protocol.
Cytotoxic effects of targeted agent alone or with chemotherapy in the treatment of adenoid cystic carcinoma: a preclinical study

Teresa Savarese,Andrea Abate,Ram Manohar Basnet,Luigi Lorini,Cristina Gurizzan,Michele Tomasoni,Davide Lombardi,Davide Tomasini,Daniela Zizioli,Maurizio Memo,Alfredo Berruti,Sara A. Bonini,Sandra Sigala,Paolo Bossi

DOI: https://doi.org/10.1038/s41598-022-14197-8

IF: 4.6

2022-06-17

Scientific Reports

Abstract:Adenoid cystic carcinoma (ACC) is a rare malignancy characterized by high incidence of relapse. When relapsing, ACC has an indolent but relentless behaviour, thus leading to a poor long-term prognosis. The treatment of choice of relapsing ACC remains surgery followed by radiotherapy, whenever feasible. Therapeutic weapons are limited to systemic drugs. The most widely used chemotherapy regimen is the combination of cisplatin and doxorubicin, however with low response rate and not long lasting; there is also a lack of alternatives for second line therapies in case of disease progression. Therefore, a more comprehensive strategy aimed at identifying at preclinical level the most promising drugs or combination is clearly needed. In this study, the cytotoxic effects of two standard chemotherapy drugs, cisplatin and doxorubicin, and of five targeted therapy-drugs was tested in vitro, on an h-TERT immortalized ACC cell line, and in vivo, on zebrafish embryos with ACC tumoral cell xenograft. Then, combinations of one standard chemotherapy drug plus one targeted therapy drug were also evaluated, in order to find the best treatment strategy for ACC. Data obtained demonstrated that both vorinostat and olaparib significantly increased the standard chemotherapy cytotoxic effects, suggesting new interesting therapeutic options for ACC.

multidisciplinary sciences
CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

Liwen Ren,Yihui Yang,Wan Li,Xiangjin Zheng,Jinyi Liu,Sha Li,Hong Yang,Yizhi Zhang,Binbin Ge,Sen Zhang,Weiqi Fu,Dexin Dong,Guanhua Du,Jinhua Wang

DOI: https://doi.org/10.1186/s12967-022-03641-y

IF: 8.44

2022-10-03

Journal of Translational Medicine

Abstract:Adrenocortical carcinoma (ACC) is an extremely rare, aggressive tumor with few effective therapeutic options or drugs. Mitotane (Mtn), which is the only authorized therapeutic drug, came out in 1970 and is still the only first-line treatment for ACC in spite of serious adverse reaction and a high recurrence rate.

medicine, research & experimental
Case report: Remarkable response to a novel combination of mitotane, etoposide, paraplatin, and sintilimab in a patient with metastatic adrenocortical carcinoma

Yan Weng,Lin Wang,Xiao-Yi Wang,Xin-Xiang Fan,Li Yan,Zhi-Hua Li,Shao-Ling Zhang

DOI: https://doi.org/10.3389/fendo.2023.1115893

IF: 6.055

2023-09-09

Frontiers in Endocrinology

Abstract:Background: Adrenocortical carcinoma (ACC) is a rare malignancy with a poor prognosis and limited treatment options for metastases. However, new effective regimens are emerging for specific conditions in metastatic ACC. Case presentation: We report a case of a 36-year-old man diagnosed with metastatic ACC who had a large left adrenal mass (158 mm × 112 mm) and multiple metastases in the liver and lungs. Genetic testing revealed a microsatellite instability-high (MSI-H) tumor, a splice mutation in MLH1, and a high tumor mutational burden (TMB). After the left adrenalectomy, he received sequential treatment with a combination of mitotane, etoposide, paraplatin (EP-M), and sintilimab. His condition has been assessed as a stable disease since the sixth cycle of the combined regimen. Conclusion: This case highlights the remarkable response of our patient's ACC with MSI-H tumor, MLH1 spice mutation, and high TMB to treatment with a novel combination of EP-M and sintilimab. Our findings suggest a promising therapeutic option for patients with similar molecular profiles.

endocrinology & metabolism
“Expression and prognostic relevance of PD-1, PD-L1 and CTLA-4 immune checkpoints in adrenocortical carcinoma”

Laura-Sophie Landwehr,Barbara Altieri,Iuliu Sbiera,Hanna Remde,Stefan Kircher,Julie Olabe,Silviu Sbiera,Matthias Kroiss,Martin Fassnacht

DOI: https://doi.org/10.1210/clinem/dgae109

2024-02-28

The Journal of Clinical Endocrinology & Metabolism

Abstract:Abstract Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with poor prognosis in advanced stages. While therapies targeting the checkpoint molecules programmed cell death 1 (PD-1), its ligand PD-L1 and the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) have revolutionized treatment in many cancers, the results in ACC were heterogeneous. Their expression in ACC has not been systematically studied and might explain the variable response to checkpoint inhibitors. The expression of PD-1, PD-L1 and CTLA-4 was examined in 162 tumor samples from 122 ACC patients by immunohistochemistry (threshold of >1%) and correlated with tumoral T lymphocyte infiltration and clinical endpoints. Finally, uni- and multivariate analyses of progression-free and overall survival were performed. PD-1 and PD-L1 were expressed in 26.5% and 24.7% of samples, respectively, with low expression in most tumor samples (median positive cells: 2.1% and 21.7%. In contrast, CTLA-4 expression was observed in 52.5% of ACC with a median of 38.4% positive cells. Positive PD-1 expression was associated with longer progression-free survival (HR: 0.50, 95% CI 0.25-0.98, p=0.04) even after considering prognostic factors. In contrast, PD-L1 and CTLA-4 did not correlate with clinical outcome. Additionally, PD-1 and PD-L1 expression correlated significantly with the amount of CD3+, CD4+, FoxP3+ and CD8+ T cells. The heterogeneous expression of PD1, PD-L1, and CTLA-4 in this large series of well-annotated ACC samples might explain the heterogeneous results of the immunotherapies in advanced ACC. In addition, PD-1 expression is a strong prognostic biomarker that can easily be applied in routine clinical care and histopathological assessment.

endocrinology & metabolism
Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial

Yu-Chun Zhu,Zhi-Gong Wei,Jing-Jing Wang,Yi-Yan Pei,Jing Jin,Dong Li,Zhi-Hui Li,Zhe-Ran Liu,Yu Min,Rui-Dan Li,Li Yang,Ji-Yan Liu,Qiang Wei,Xing-Chen Peng

DOI: https://doi.org/10.1038/s41467-024-54661-9

IF: 16.6

2024-11-29

Nature Communications

Abstract:Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy with a poor prognosis. Therapeutic options for patients with advanced ACC who have failed standard treatments are limited. Single-agent immunotherapy as a second-line treatment has shown unsatisfactory clinical outcomes. This phase II trial (NCT04318730) evaluated the efficacy and safety of the PD-1 inhibitor camrelizumab combined with the VEGFR inhibitor apatinib in previously treated advanced ACC. The primary endpoint was objective response rate (ORR). The secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. A total of 21 patients with advanced ACC received at least one dose of camrelizumab and apatinib. The ORR was 52% (95% CI, 30−74%), meeting the primary endpoint, and the disease control rate (DCR) was 95% (95% CI, 76−100%). The median PFS was 13.3 months (95% CI, 8.4−NE), and the median OS was 20.9 months (95% CI, 11.0−NE). The most common grade 3−4 treatment-related adverse events were alanine aminotransferase elevation, aspartate aminotransferase elevation, and lymphopenia. Predefined exploratory analyses indicated that patients with higher peripheral blood CXCR3 + CD8 + T cell abundance, lower immunosuppressive CD4 + T cell abundance, and higher overlap of clonotypes between tumor-infiltrating T cells and circulating T cells, were more likely to respond favorably to the combined therapy.

multidisciplinary sciences
Abstract 5835: Genome-Wide CRISPR gene knockout screens combined with selpercatinib identifies potent combination therapies for RET driven medullary thyroid carcinoma

Abdelrahman Rahmy,Arwa Fallatah,David Milewski,Meijie Tian,Young Song,Yong Kim,Hsien-Chao Chou,Xinyu Wen,Chaoyu Wang,Jun Wei,Robert Hawley,John Glod,Javed Khan

DOI: https://doi.org/10.1158/1538-7445.am2024-5835

IF: 11.2

2024-03-24

Cancer Research

Abstract:Background: Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor driven primarily by activating mutations in the RET proto-oncogene. It accounts for approximately 13% of thyroid cancer-related deaths. Total thyroidectomy is the main treatment option for MTC patients; however, its efficacy is limited due to the high prevalence of metastatic disease at diagnosis. Vandetanib, cabozantinib, and selpercatinib are RET signaling inhibitors (RETi), that have been approved for treating advanced MTC. Despite their effectiveness, many patients relapse or have refractory disease due to eventual resistance to these RETis. Methods: In our study, we employed genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) gene knockout (KO) in MTC cell lines treated with selpercatinib or vehicle to investigate the genetic mechanisms of resistance or sensitivity to RETi. Our overarching goal was to identify potential synergistic or additive drug combinations that may prevent or treat resistant disease. Results: Our research identified key genes and pathways confirming the sensitivity or resistance of MTC cells to RETi. Notably, apoptotic genes along with RAS and mTOR signaling pathways were found to play a significant role in resistance development. Knocking out negative regulators of these pathways (such as NF1 and TSC2) conferred growth advantages to cells treated with RETi. Alternatively, knocking out BCL2, an antiapoptotic protein, led to increased lethality. These findings suggested that targeting RAS, mTOR, or antiapoptotic pathways in conjunction with RETi may be synergistic or have additive activity. To validate the CRISPR screening, we selectively knocked down NF1 in MTC cells and found it led to a nearly two-fold increase in IC50 for selpercatinib. Furthermore, in-vitro and in-vivo testing confirmed significant synergistic activity when using the combination of trametinib, an MEK inhibitor (MEKi; downstream of the RAS pathway), with selpercatinib. Conclusions and Future Directions: We have identified a potent synergistic combination of MEKi with RETi as a novel synergistic drug combination to treat MTC, which may also prevent resistance to RETi. These results will be translated to patients through clinical trials conduced at the NCI. Citation Format: Abdelrahman Rahmy, Arwa Fallatah, David Milewski, Meijie Tian, Young Song, Yong Kim, Hsien-Chao Chou, Xinyu Wen, Chaoyu Wang, Jun Wei, Robert Hawley, John Glod, Javed Khan. Genome-Wide CRISPR gene knockout screens combined with selpercatinib identifies potent combination therapies for RET driven medullary thyroid carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 5835.

oncology
Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma

Nai-Yun Sun,Suresh Kumar,Yoo Sun Kim,Diana Varghese,Arnulfo Mendoza,Rosa Nguyen,Reona Okada,Karlyne Reilly,Brigitte Widemann,Yves Pommier,Fathi Elloumi,Anjali Dhall,Mayank Patel,Etan Aber,Cristie Contreras-Burrola,Rosie Kaplan,Dan Martinez,Jennifer Pogoriler,Amber K. Hamilton,Sharon J. Diskin,John M. Maris,Robert W. Robey,Michael M. Gottesman,Jaydira Del Rivero,Nitin Roper

DOI: https://doi.org/10.1101/2024.10.09.617077

2024-10-11

Abstract:Immunotherapeutic targeting of cell surface proteins is an increasingly effective cancer therapy. However, given the limited number of current targets, the identification of new surface proteins, particularly those with biological importance, is critical. Here, we uncover delta-like non-canonical Notch ligand 1 (DLK1) as a cell surface protein with limited normal tissue expression and high expression in multiple refractory adult metastatic cancers including small cell lung cancer (SCLC) and adrenocortical carcinoma (ACC), a rare cancer with few effective therapies. In ACC, ADCT-701, a DLK1 targeting antibody-drug conjugate (ADC), shows potent in vitro activity among established cell lines and a new cohort of patient-derived organoids as well as robust in vivo anti-tumor responses in cell line-derived and patient-derived xenografts. However, ADCT-701 efficacy is overall limited in ACC due to high expression and activity of the drug efflux protein ABCB1 (MDR1, P-glycoprotein). In contrast, ADCT-701 is extremely potent and induces complete responses in DLK1+ ACC and SCLC in vivo models with low or no ABCB1 expression. Genetic deletion of DLK1 in ACC dramatically downregulates ABCB1 and increases ADC payload and chemotherapy sensitivity through NOTCH1-mediated adrenocortical de-differentiation. Single cell RNA-seq of ACC metastatic tumors reveals significantly decreased adrenocortical differentiation in DLK low or negative cells compared to DLK1 positive cells. This works identifies DLK1 as a novel immunotherapeutic target that regulates tumor cell plasticity and chemoresistance in ACC. Our data support targeting DLK1 with an ADC in ACC and neuroendocrine neoplasms in an active first-in-human phase I clinical trial ( ).

Cancer Biology
Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches

Divya Chukkalore,Kira MacDougall,Viraj Master,Mehmet Asim Bilen,Bassel Nazha

DOI: https://doi.org/10.1093/oncolo/oyae029

2024-02-21

The Oncologist

Abstract:Abstract Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy in the advanced setting with poor prognosis. This narrative review provides an overview of the epidemiology of ACC and its molecular pathogenesis with a summary of the main involved signaling pathways. We then provide an update on the clinical presentation, diagnosis, and current management strategies of both localized and metastatic disease from a multidisciplinary perspective. We highlight the debate around the use of mitotane in the adjuvant setting and review the use of combination chemotherapy with etoposide, doxorubicin, and cisplatin. The review also focuses on emerging data providing hope for the use of immune checkpoint inhibitors and targeted therapies in ACC with a summary of ongoing trials.

oncology
The efficacy of adjuvant mitotane therapy and radiotherapy following adrenalectomy in patients with adrenocortical carcinoma: A systematic review and meta-analysis

Ichiro Tsuboi,Mehdi Kardoust Parizi,Akihiro Matsukawa,Stefano Mancon,Marcin Miszczyk,Robert J. Schulz,Tamás Fazekas,Anna Cadenar,Ekaterina Laukhtina,Tatsushi Kawada,Satoshi Katayama,Takehiro Iwata,Kensuke Bekku,Koichiro Wada,Mesut Remzi,Pierre I. Karakiewicz,Motoo Araki,Shahrokh F. Shariat

DOI: https://doi.org/10.1016/j.urolonc.2024.09.014

IF: 2.954

2024-10-10

Urologic Oncology Seminars and Original Investigations

Abstract:Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with a high recurrence rate after surgical therapy with curative intent. Adjuvant radiotherapy (RT) and mitotane therapy have been proposed as options following the adrenalectomy. However, the efficacy of adjuvant RT or mitotane therapy remains controversial. We aimed to evaluate the efficacy of adjuvant therapy in patients who underwent adrenalectomy for localised ACC. The PubMed, Scopus, and Web of Science databases were queried on March 2024 for studies evaluating adjuvant therapies in patients treated with surgery for localized ACC (PROSPERO: CRD42024512849). The endpoints of interest were overall survival (OS) and recurrence-free survival (RFS). Hazard ratios (HR) with 95% confidence intervals (95%CI) were pooled in a random-effects model meta-analysis. One randomized controlled trial ( n = 91) and eleven retrospective studies ( n = 4,515) were included. Adjuvant mitotane therapy was associated with improved RFS (HR: 0.63, 95%CI: 0.44-0.92, p = 0.016), while adjuvant RT did not reach conventional levels of statistical significance (HR:0.79, 95%CI:0.58-1.06, p = 0.11). Conversely, Adjuvant RT was associated with improved OS (HR:0.69, 95%CI:0.58-0.83, p<0.001), whereas adjuvant mitotane did not (HR: 0.76, 95%CI: 0.57-1.02, p = 0.07). In the subgroup analyses, adjuvant mitotane was associated with better OS (HR:0.46, 95%CI: 0.30-0.69, p < 0.001) and RFS (HR:0.56, 95%CI: 0.32-0.98, p = 0.04) in patients with negative surgical margin. Both adjuvant RT and mitotane were found to be associated with improved oncologic outcomes in patients treated with adrenalectomy for localised ACC. While adjuvant RT significantly improved OS in general population, mitotane appears as an especially promising treatment option in patients with negative surgical margin. These data can support the shared decision-making process, better understanding of the risks, benefits, and effectiveness of these therapies is still needed to guide tailored management of each individual patient.

oncology,urology & nephrology
A 3D adrenocortical carcinoma tumor platform for preclinical modeling of drug response and matrix metalloproteinase activity

Priya H Dedhia,Hemamylammal Sivakumar,Marco A Rodriguez,Kylie G Nairon,Joshua M Zent,Xuguang Zheng,Katie Jones,Liudmila V Popova,Jennifer L Leight,Aleksander Skardal

DOI: https://doi.org/10.1038/s41598-023-42659-0

2023-09-19

Abstract:Adrenocortical carcinoma (ACC) has a poor prognosis, and no new drugs have been identified in decades. The absence of drug development can partly be attributed to a lack of preclinical models. Both animal models and 2D cell cultures of ACC fail to accurately mimic the disease, as animal physiology is inherently different than humans, and 2D cultures fail to represent the crucial 3D architecture. Organoids and other small 3D in vitro models of tissues or tumors can model certain complexities of human in vivo biology; however, this technology has largely yet to be applied to ACC. In this study, we describe the generation of 3D tumor constructs from an established ACC cell line, NCI-H295R. NCI-H295R cells were encapsulated to generate 3D ACC constructs. Tumor constructs were assessed for biomarker expression, viability, proliferation, and cortisol production. In addition, matrix metalloproteinase (MMP) functionality was assessed directly using fluorogenic MMP-sensitive biosensors and through infusion of NCI-H295R cells into a metastasis-on-a-chip microfluidic device platform. ACC tumor constructs showed expression of biomarkers associated with ACC, including SF-1, Melan A, and inhibin α. Treatment of ACC tumor constructs with chemotherapeutics demonstrated decreased drug sensitivity compared to 2D cell culture. Since most tumor cells migrate through tissue using MMPs to break down extracellular matrix, we validated the utility of ACC tumor constructs by integrating fluorogenic MMP-sensitive peptide biosensors within the tumor constructs. Lastly, in our metastasis-on-a-chip device, NCI-H295R cells successfully engrafted in a downstream lung cell line-based construct, but invasion distance into the lung construct was decreased by MMP inhibition. These studies, which would not be possible using 2D cell cultures, demonstrated that NCI-H295R cells secreted active MMPs that are used for invasion in 3D. This work represents the first evidence of a 3D tumor constructs platform for ACC that can be deployed for future mechanistic studies as well as development of new targets for intervention and therapies.
Single Nuclei Sequencing Reveals Replication Stress in Adrenocortical Carcinoma

Liudmila V. Popova,Elizabeth A. R. Garfinkle,Daniel M. Chopyk,Jaye B. Navarro,Adithe Rivaldi,Yaoling Shu,Elena Lomonosova,John E Phay,Barbra S Miller,Swati Sattuwar,Elaine R Mardis,Katherine E Miller,Priya H Dedhia

DOI: https://doi.org/10.1101/2024.09.30.615695

2024-10-28

Abstract:Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a poor prognosis and limited treatment options. Bulk genomic characterization of ACC has not yielded obvious therapeutic or immunotherapeutic targets, yet novel therapies are needed. We hypothesized that elucidating the intratumoral cellular heterogeneity by single nuclei RNA sequencing analyses would yield insights into potential therapeutic vulnerabilities of this disease. In addition to characterizing the immune cell and fibroblast landscape, our analyses of single nuclei gene expression profiles identified an adrenal cortex cell cluster exhibiting a program of replication stress and DNA damage response in primary and metastatic ACC. In vitro assessment of replication stress and DNA damage response using an ACC cell line and a series of newly-derived hormonally active patient-derived tumor organoids revealed ATR sensitivity. These findings provide novel mechanistic insight into ACC biology and suggest that an underlying dependency on ATR may be leveraged therapeutically in advanced ACC.

Cancer Biology
Abstract 7550: KB-0742, an oral highly selective CDK9 inhibitor, demonstrates preclinical activity in transcription factor fusion driven adenoid cystic carcinoma patient-derived models

Michael R. McKeown,Luis A. Carvajal,Tressa R. Hood,Nicole S. Burr,Jeffrey Kaufman,Adam Boynton,Kameron Mori,Tessa DesRochers,Michael Wick,Charles Y. Lin,Jorge F. DiMartino

DOI: https://doi.org/10.1158/1538-7445.am2024-7550

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Adenoid Cystic Carcinoma (ACC) is an aggressive rare type of cancer of the secretory glands with no approved targeted therapy and high unmet clinical need. Deregulated transcription driven by MYB-NFIB or MYBL1-NFIB transcription factor (TF) fusions are a hallmark of ACC pathogenesis. More aggressive disease and resistance to therapy has been associated with co-mutation in NOTCH. Although direct targeting of oncogenic TF fusions has remained challenging, targeting of their activity via transcriptional cofactors has emerged as an attractive and clinically actionable strategy. Cyclin-dependent kinase 9 (CDK9) is a key potentiator of TF activity via its ability to act both as an upstream regulator of TF expression and a downstream cofactor. KB-0742 is a potent, selective, and orally bioavailable inhibitor of CDK9 with a long plasma half-life. KB-0742 is being studied in an ongoing Phase 1/2 study (NCT04718675) in advanced solid tumors including ACC. KB-0742 has demonstrated on-mechanism, single agent anti-tumor activity and a manageable safety profile in heavily pre-treated patients (0-11 prior lines of therapy) with transcriptionally addicted solid tumors. Here we present the preclinical rationale for targeting of oncogenic fusion TF activity in ACC. XenoSTART Patient-Derived Xenograft (XPDX) models were established from viable human tumor tissue for in vivo and ex vivo testing. Cell viability was assessed by CellTiter GLO reagent and phase imaging. Changes in MYB-fusion transcripts were assessed by RNA-Seq. Tumor Fragments (~70 mg) from ACCx5M1, ACCx6, ACCx9, ACCx11 models were implanted into athymic nude mice. Animals were treated with either vehicle (normal saline) or 60 mg/kg KB-0742 on a Q3D/week until tumors reached 2500 mm3 or up to 60 days post start of treatment. In a retrospective analysis using real world data, ACC has a low incidence of genomic instability and high rates of MYB fusions detectable by RNA-seq, making immunotherapy challenging but creating an opportunity for targeting MYB transcription. In primary MYB-fusion positive and NOTCH co-mutated patient-derived spheroid models, KB-0742 treatment induced strong antiproliferative activity and cytotoxicity. Importantly, KB-0742 demonstrated stronger cytotoxic effects when compared to historical control agents. In XPDXs, CDK9 inhibition with KB-0742 resulted in antiproliferative activity and stronger tumor growth inhibition in MYB-fusion positive and NOTCH co-mutated tumor models compared to MYB-fusion positive only models.These data demonstrate KB-0742 is effective in preclinical models of ACC suggesting KB-0742 may be a promising therapeutic option for ACC patients. KB-0742 is currently being evaluated in a phase 1/2 dose-escalation and cohort expansion trial in patients with ACC and other transcriptionally addicted tumors (NCT04718675). Citation Format: Michael R. McKeown, Luis A. Carvajal, Tressa R. Hood, Nicole S. Burr, Jeffrey Kaufman, Adam Boynton, Kameron Mori, Tessa DesRochers, Michael Wick, Charles Y. Lin, Jorge F. DiMartino. KB-0742, an oral highly selective CDK9 inhibitor, demonstrates preclinical activity in transcription factor fusion driven adenoid cystic carcinoma patient-derived models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7550.

oncology
The Efficacy and Safety of Immune Checkpoint Inhibitors in Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis

Obada Ababneh,Alina Ghazou,Mohmmad Alawajneh,Saleh Alhaj Mohammad,Abdullah Bani-Hani,Nasr Alrabadi,Aditya Shreenivas

DOI: https://doi.org/10.3390/cancers16050900

2024-02-23

Cancers

Abstract:Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of different malignancies. However, their efficacy in advanced adrenocortical carcinoma (ACC) remains uncertain. Thus, we conducted a systematic review and meta-analysis to summarize the efficacy and tolerability of ICIs in patients with advanced ACC. We searched PubMed, Scopus, and CENTRAL for studies that used ICIs in ACC. Studies with more than five patients were included in the meta-analysis of the objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS), and grade 3/4 adverse events. Twenty studies with 23 treatment arms and 250 patients were included. Single-agent anti-PD1 or anti-PD-L1 treatment was utilized in 13 treatment arms, whereas an anti-PD1 or anti-PD-L1 and anti-CTLA4 combination was used in 4 treatment arms. Other anti-PD1- or anti-PD-L1-based combinations were used in five treatment arms. The ORR was 14% (95% CI = 10–19%, I2 = 0%), and the DCR was 43% (95% CI = 37–50%, I2 = 13%). The combination anti-PD1- or anti-PD-L1-based treatment strategies did not correlate with higher responses compared with monotherapy. The median OS was 13.9 months (95% CI = 7.85–23.05), and the median PFS was 2.8 months (95% CI = 1.8–5.4). ICIs have a modest efficacy in advanced ACC but a good OS. Further studies are needed to investigate predictive biomarkers for ICI response and to compare ICI-based strategies with the current standard of care.

oncology

Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer

Molecular Cluster Mining of Adrenocortical Carcinoma Via Multi-Omics Data Analysis Aids Precise Clinical Therapy.

Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics

The effectiveness of targeted therapy for recurrence or metastasis adenoid cystic carcinoma: a systematic review and meta-analysis

Comprehensive genomic analysis of adrenocortical carcinoma reveals genetic profiles associated with patient survival

A meta-analysis of overall survival and response in metastatic adrenocortical carcinoma: A review of 23 prospective trials of 880 patients.

Combined inhibition of JAK1/2 and DNMT1 by newly identified small-molecule compounds synergistically suppresses the survival and proliferation of cervical cancer cells

Identification of a Novel Oral Small-Molecule JAK1/2 Inhibitor and Its Potent Synergistic Drug Combinations Against Cervical Cancer

Cytotoxic effects of targeted agent alone or with chemotherapy in the treatment of adenoid cystic carcinoma: a preclinical study

CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

Case report: Remarkable response to a novel combination of mitotane, etoposide, paraplatin, and sintilimab in a patient with metastatic adrenocortical carcinoma

“Expression and prognostic relevance of PD-1, PD-L1 and CTLA-4 immune checkpoints in adrenocortical carcinoma”

Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial

Abstract 5835: Genome-Wide CRISPR gene knockout screens combined with selpercatinib identifies potent combination therapies for RET driven medullary thyroid carcinoma

Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma

Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches

The efficacy of adjuvant mitotane therapy and radiotherapy following adrenalectomy in patients with adrenocortical carcinoma: A systematic review and meta-analysis

A 3D adrenocortical carcinoma tumor platform for preclinical modeling of drug response and matrix metalloproteinase activity

Single Nuclei Sequencing Reveals Replication Stress in Adrenocortical Carcinoma

Abstract 7550: KB-0742, an oral highly selective CDK9 inhibitor, demonstrates preclinical activity in transcription factor fusion driven adenoid cystic carcinoma patient-derived models

The Efficacy and Safety of Immune Checkpoint Inhibitors in Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis